Achmea IM to vote against pharma pay unless tied to access to medicine

For Responsible Investor, Paul Verney writes about the decision of Achmea Investment Management to vote against say-on-pay proposals at pharmaceutical companies which have not integrated access to medicine into executive remuneration. The article references the meetings Achmea Investment Management had with the Access to Medicine Foundation to develop a set of metrics on access that pharmaceutical companies could integrate into executive compensation.